Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY) Shows Short-Term Momentum But Remains Overvalued
![]() |
Near-term technical flips hint at episodic rallies, yet core valuation metrics place the shares above fair value. Recent corporate updates underline clinical progress and strategic partnerships that support longer-term pipeline optionality. |








